-+ 0.00%
-+ 0.00%
-+ 0.00%

Stephens & Co. Maintains Overweight on Kymera Therapeutics, Raises Price Target to $100

Benzinga·03/02/2026 14:22:36
Listen to the news
Stephens & Co. analyst Sudan Loganathan maintains Kymera Therapeutics (NASDAQ:KYMR) with a Overweight and raises the price target from $95 to $100.